Charlie Hao
Chief Scientific Officer Degron Therapeutics
Seminars
Thursday 28th January 2027
Panel Discussion: Deploying Molecular Glues to Tackle Neurodegeneration’s Toughest Targets
2:00 pm
- How can molecular glues be leveraged to target pathogenic protein aggregates and drive the selective clearance of disease-causing proteins across Alzheimer’s, Parkinson’s, and Huntington’s disease?
- What strategies are proving most effective for engineering brain-penetrant molecular glues that improve CNS exposure and target engagement while enhancing the translational potential of neurodegeneration programs?
- How can target engagement be most effectively validated in disease-relevant neuronal models to better understand therapeutic impact and de-risk progression into clinical development?
